ASH 2023 | Results of the PERSEUS trial: D-VRd with D-R maintenance in transplant-eligible newly diagnosed MM
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the PERSEUS trial (NCT03710603), a Phase III, randomized study evaluating subcutaneous daratumumab (D) in combination with VRd (bortezomib, lenalidomide (R) and dexamethasone) followed by D-R maintenance compared to VRd with R maintenance in transplant eligible patients with newly diagnosed multiple myeloma (MM). The study showed that D-VRd significantly improved progression-free survival (PFS) and increased depth of response in this patient population, with a safety profile corresponding to previous reports for all treatments. These data demonstrate a clinically significant benefit of the quadruplet regimen and support its recommendation as the new standard of care in transplant-eligible newly diagnosed MM. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
The PERSEUS trial is a very important prospective, randomized trial in transplant eligible, newly diagnosed patients with multiple myeloma. And there are two treatment arms. The standard arm consists of a combination of bortezomib, lenalidomide, and dexamethasone as an induction followed by high-dose therapy and then consolidation. And the investigational arm is the same but with the addition of daratumumab...
The PERSEUS trial is a very important prospective, randomized trial in transplant eligible, newly diagnosed patients with multiple myeloma. And there are two treatment arms. The standard arm consists of a combination of bortezomib, lenalidomide, and dexamethasone as an induction followed by high-dose therapy and then consolidation. And the investigational arm is the same but with the addition of daratumumab. Subsequently, the patients also get to be randomized to lenalidomide or daratumumab with lenalidomide. So the primary endpoint of the study is progression-free survival and this was reached. So there was a significant improvement in progression-free survival in favor of the quadruplet which included lenalidomide, bortezomib, and daratumumab. And so I believe this is a practice changing trial that will lead to the formal approval of this quadruplet in Europe as well.
Read more...
Disclosures
Honoraria: Amgen, AbbVie, Takeda, Beigene, BMS, GSK, Janssen, Menarini, Regeneron, Sanofi
